Narrow search
Showing 1 - 10 of 9,460
Cover Image
When are assets compementary? : star scientists, strategic alliances, and innovation in the pharmaceutical industry
Hess, Andrew M.; Rothärmel, Frank T. - In: Strategic management journal 32 (2011) 8, pp. 895-909
Persistent link: https://www.econbiz.de/10009237567
Cover Image
Authorized generic entry prior to patent expiry : reassessing incentives for independent generic entry
Appelt, Silvia - 2010
Patent holders frequently attempt to mitigate the loss of monopoly power by authorizing generic entry prior to patent expiry (early entry). Competition in off-patent pharmaceutical markets may be adversely affected if early entry substantially impairs the attractiveness of subsequent market...
Persistent link: https://www.econbiz.de/10003964934
Cover Image
Authorized generic entry prior to patent expiry : reassessing incentives for independent generic entry
Appelt, Silvia - 2010
Patent holders attempt to mitigate the loss of monopoly power by authorizing generic entry prior to patent expiry (early entry). Off-patent competition may be adversely affected if early entry substantially lowers the attractiveness of subsequent generic entry. This study assesses the impact of...
Persistent link: https://www.econbiz.de/10008939409
Cover Image
The Effects of Detailing on Prescribing Decisions Under Quality Uncertainty
Ching, Andrew T.; Ishihara, Masakazu - 2010
Motivated by recent empirical findings on the relationship between new clinical evidence and the effectiveness of detailing, this paper develops a new structural model of detailing and prescribing decisions under the environment where both manufacturers and physicians are uncertain about drug...
Persistent link: https://www.econbiz.de/10014048404
Cover Image
The impact of public basic research on industrial innovation : evidence from the pharmaceutical industry
Toole, Andrew A. - 2011 - This version: March 2011
While most economists believe that public scientific research fuels industry innovation and economic growth, systematic … size as a significant driver of drug innovation in the pharmaceutical industry, but they did not find any evidence … supporting science-driven innovation from publicly funded research. This paper uses new data on biomedical research investments …
Persistent link: https://www.econbiz.de/10009374417
Cover Image
Patents, price controls, and pharmaceuticals : considerations from political economy
Djolov, George G. - In: The journal of world intellectual property 6 (2003) 4, pp. 611-631
Persistent link: https://www.econbiz.de/10001872381
Cover Image
Unpacking the effects of adverse regulatory events : Evidence from pharmaceutical relabeling
Higgins, Matthew J.; Yan, Xin; Chatterjee, Chirantan - In: Research policy : policy, management and economic … 50 (2021) 1, pp. 1-15
Persistent link: https://www.econbiz.de/10012663313
Cover Image
Public-private and private-private collaboration as pathways for socially beneficial innovation : evidence from antimicrobial drug-development tasks
Arslan, Birgul; Vasudeva, Gurneeta; Hirsch, Elizabeth B. - In: Academy of Management journal : AMJ 67 (2024) 2, pp. 554-582
Persistent link: https://www.econbiz.de/10014546516
Cover Image
Modeling inter-regional patient mobility : does distance go far enough?
Irlacher, Michael; Pennerstorfer, Dieter; Renner, … - 2021
This paper estimates a theory-guided gravity equation of regional patient ows. In our model, a patient's choice to consult a physician in a particular region depends on a measure of spatial accessibility that accounts for the exact locations of both patients and physicians. Introducing this...
Persistent link: https://www.econbiz.de/10012494336
Cover Image
Pharmaceutical innovation and health outcomes : empirical evidence from Taiwan
Hsieh, Chee-Ruey; Lo, Kuang-ta Vance; Hong, Yichen; … - In: Pharmaceutical innovation : incentives, competition, …, (pp. 242-261). 2007
Persistent link: https://www.econbiz.de/10003499023